GILD34:BVMF
Gilead Sciences Inc BDR
R$65,81
0,00%
(0,00) 1D
16 Okt., 16:56:00 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD34...
Open
R$66,36
High
R$66,41
Low
R$65,81
Mkt. cap
193,67 mjd
Avg. vol.
261,00
Volume
1,78 k
52-wk high
R$67,38
52-wk low
R$51,33
Shares outstanding
1,24 mjd
No. of employees
17 k
Open
R$66,36
High
R$66,41
Low
R$65,81
Mkt. cap
193,67 mjd
Avg. vol.
261,00
Volume
1,78 k
52-wk high
R$67,38
52-wk low
R$51,33
Shares outstanding
1,24 mjd
No. of employees
17 k
News stories
From web sources and news partners
ad-hoc-news.de
·
27 minute gelede
Gilead Sciences stock sits 2.32 percent below its yearly high
ad-hoc-news.de
·
1 uur gelede
Gilead Sciences stock pre-market at EUR 139.78: biotech group slightly higher
The Motley Fool
·
14 uur gelede
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
Simply Wall Street
·
1 dag gelede
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences Inc BDR
CEODaniel O'Day
Employees17 k
Founded22 Jun. 1987
HeadquartersFoster City, Kalifornië, Verenigde State van Amerika
Sector-
Websitegilead.com